Unknown

Dataset Information

0

Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naive Patients with HIV-1 Infection: the REMAIN Study.


ABSTRACT: Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-life clinical data are limited.We evaluated the long-term use of ATV/r as a component of antiretroviral combination therapy in the real-life setting in the REMAIN study.This was an observational cohort study conducted at sites across Germany, Portugal, and Spain. Retrospective historical and prospective longitudinal follow-up data were extracted every six months from medical records of HIV-infected treatment-naïve patients aged ? 18 years initiating a first-line ATV/r-containing regimen.Eligible patients (n = 517) were followed up for a median of 3.4 years. The proportion remaining on ATV/r at 5 years was 51.5% with an estimated Kaplan-Meier median time to treatment discontinuation of 4.9 years. Principal reasons for discontinuation were adverse events (15.9%; 8.9% due to hyperbilirubinemia) and virologic failure (6.8%). The Kaplan-Meier probability of not having virologic failure (HIV-1 RNA < 50 copies/mL) was 0.79 (95% CI: 0.75, 0.83) at five years. No treatment-emergent major PI resistance occurred. ATV/r was generally well tolerated during long-term treatment with no significant changes in estimated glomerular filtration rate over five years.In a real-life clinical setting over five years, treatment-naïve patients with HIV-1 infection initiating an ATV/r-based regimen showed sustained virologic suppression, an overall treatment persistence rate of 51.5%, an absence of treatment-emergent major PI resistance mutations at virologic failure, a long-term safety profile consistent with that observed in clinical trials, and no significant decline in renal function.

SUBMITTER: Teofilo E 

PROVIDER: S-EPMC4975100 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.

Teófilo Eugénio E   Rocha-Pereira Nuno N   Kuhlmann Birger B   Antela Antonio A   Knechten Heribert H   Santos Jesús J   Jiménez-Expósito Maria Jesús MJ  

HIV clinical trials 20160201 1


<h4>Background</h4>Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-life clinical data are limited.<h4>Objective</h4>We evaluated the long-term use of ATV/r as a component of antiretroviral combination therapy in the real-life setting in the REMAIN study.<h4>Methods</h4>This was an observational cohort study conducted at sites across Germ  ...[more]

Similar Datasets

| S-EPMC3019087 | biostudies-literature
| S-EPMC6117059 | biostudies-literature
| S-EPMC3698683 | biostudies-literature
| S-EPMC3448095 | biostudies-literature
| S-EPMC2758664 | biostudies-literature
| S-EPMC4577040 | biostudies-literature
2020-02-05 | GSE137247 | GEO
| S-EPMC2680942 | biostudies-literature
| S-EPMC4428759 | biostudies-literature
| S-EPMC9962206 | biostudies-literature